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PTH : parathyroid hormone ; PHPT : primary hyperparathyroidism ; SHPT : secondary 34 
hyperparathyroidism ; N-PHPT : normocalcemic primary hyperparathyroidism; CKD-MBD : 35 
chronic kidney disease (CKD)-related mineral and bone disorders (MBD) ; ULN : upper limit 36 
of normal ; 25OHD : 25-hydroxyvitamin D ; eGFR : estimated glomerular filtration rate ; 37 
BMI : body mass index ; BMD : bone mineral density ; LOQ : limit of quantification ; IQR : 38 
interquartile range 39 
40 
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Abstract 41 
Objective: To determine PTH reference values in French healthy adults, taking into account 42 
serum 25OHD, renal function, age, gender, and BMI. 43 
Participants and main biological measurements: We studied 898 healthy subjects (432 44 
women) aged 18-89 years with a normal BMI and eGFR, 81 patients with surgically proven 45 
primary hyperparathyroidism (PHPT), and 264 dialysis patients. 25OHD and 3
rd
-generation 46 
PTH assays were implemented on the LIAISON XL platform. 47 
Results: Median PTH and 25OHD values in the 898 healthy subjects were 18.8 ng/L and 23.6 48 
ng/mL respectively. PTH was lower in subjects with 25OHD >30 ng/mL than in those with 49 
lower values. Among the 183 subjects with 25OHD >30 ng/mL, those aged >60 years (n=31) 50 
had higher PTH values than younger subjects, independently of 25OHD, BMI and eGFR 51 
(p<0.001). Given the small number of subjects aged >60 years, we adopted the 95% CI of 52 
PTH values for the entire group of 183 vitamin D-replete subjects (9.4-28.9 ng/L) as our 53 
reference values. With 28.9 ng/L as the upper limit of normal (ULN) rather than the 54 
manufacturer’s ULN of 38.4 ng/L, the percentage of PHPT patients with “high” PTH values 55 
rose to 90.1% from 66.6% (p<0.001), and 18.6% of the dialysis patients were classified 56 
differently in view of the KDIGO target range (2 to 9 times the ULN). 57 
Conclusion: When only subjects with 25OHD >30 ng/mL were included in the reference 58 
population, the PTH ULN fell by 22.4%, diagnostic sensitivity for PHPT improved, and the 59 
classification of dialysis patients was modified. 60 
 61 
Key words: parathyroid hormone; vitamin D; reference values; primary hyperparathyroidism; 62 
dialysis 63 
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Introduction 65 
With the advent of automated assays, serum parathyroid hormone (PTH) is frequently 66 
measured in clinical practice. Second-generation assays cross-react with N-terminal truncated 67 
PTH fragments (7-84 PTH), while third-generation assays do not detect 7-84 PTH but 68 
measure, in addition to 1-84 PTH, a post-translational form called amino-PTH, that is 69 
overproduced in many patients with parathyroid carcinomas 
1, 2
. Guidelines for the diagnosis 70 
of asymptomatic primary hyperparathyroidism (PHPT) 
3
, and also the KDIGO guidelines 
4
, 71 
emphasize that 2
nd
- and 3
rd
-generation PTH assays have similar clinical value for the 72 
diagnosis of PHPT, and for the follow-up of chronic kidney disease (CKD)-related mineral 73 
and bone disorders (MBD). As a result, more and more clinical laboratories worldwide are 74 
using 3
rd
-generation PTH assays routinely. 75 
A serum PTH concentration above the upper limit of normal [ULN] reflects either secondary 76 
hyperparathyroidism (SHPT) when associated with hypocalcemia, or PHPT when associated 77 
with hypercalcemia. In patients with a normal total calcemia, an elevated PTH level may 78 
correspond either to SHPT or to normocalcemic PHPT (N-PHPT).  PHPT is all the more 79 
probable in case of high normal serum calcium levels 
5
. A definite proportion of patients who 80 
fall in this subgroup have elevated ionized calcium. In dialysis patients, KDIGO guidelines 81 
recommend maintaining serum PTH within 2 to 9 times the ULN 
4
. The definition of the PTH 82 
ULN is therefore of prime importance for the care of these numerous patients, and this raises 83 
questions as to the inclusion/exclusion criteria that should be applied when recruiting a 84 
reference population to establish PTH normal values. The exclusion criteria should include 85 
any situation potentially inducing an increase or decrease in the PTH concentration. This 86 
includes a low serum 25-hydroxyvitamin D (25OHD) concentration, which is highly frequent 87 
in the general population 
6
 and is thus likely to be prevalent in an apparently healthy group 88 
recruited to establish normal PTH values. Excluding subjects with low 25OHD from a 89 
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reference population for serum PTH reference values is strongly recommended in the two 90 
most recent guidelines on the diagnosis and management of asymptomatic PHPT 
7, 8
. We have 91 
demonstrated in several studies that this lowers the serum PTH ULN by 20-35% depending 92 
on the assay 
6, 9-12
.  93 
Another point which should be taken into account is renal function. Indeed, PTH levels can 94 
rise when the eGFR is below 60 mL/min/1.73 m² 
4
, and some apparently healthy subjects, 95 
especially those older than 60 years, may have a low eGFR. 96 
Another issue is whether the PTH reference population should be stratified according to 97 
factors such as age, gender, menopausal status, body mass index (BMI), and race.  98 
The aim of this study was to determine PTH reference values for an automated 3
rd
–generation 99 
assay in French healthy adults, stratifying the results according to vitamin D status, renal 100 
function, gender, age and BMI. We also determined the frequency of high PTH levels in a 101 
series of patients with surgically proven PHPT, and the classification of dialysis patients 102 
according to KDIGO guidelines. 103 
Subjects and methods 104 
Subjects 105 
We enrolled healthy volunteers who participated in the VARIETE study, a population-based 106 
cross-sectional study designed to recruit a reference population normal serum IGF-I values in 107 
adults (ClinicalTrials.gov identifier: NCT01831648). They were recruited between January 108 
2011 and February 2012 by the clinical research units of 10 university hospitals distributed 109 
throughout France. Inclusion criteria were a normal physical work-up (weight, height, blood 110 
pressure, nutritional status and gonadal/sexual status), normal laboratory values determined 111 
after an overnight fast (plasma sodium, potassium, calcium, phosphate, creatinine, glycemia, 112 
total cholesterol, liver enzymes, TSH, blood cell counts, albuminemia, prothrombin time, and 113 
HIV and HCV serology), age 18-89 years and BMI between 19 and 28 kg/m², and a written 114 
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informed consent to participate in the study. The exclusion criteria were a medical history of 115 
thyroid, renal, hepatic, cardiovascular, pulmonary, intestinal or psychiatric disorders, cancer, 116 
epilepsy, intercurrent illness occurring during the week preceding inclusion, current 117 
consumption of tobacco or other toxics, and treatment potentially modifying IGF-I or 118 
calcium/phosphorus metabolism (antiandrogens or antiestrogens, loop diuretics, 119 
hydrochlorothiazide, CYP-inducing drugs). In addition to the blood samples necessary for the 120 
screening biological evaluation, 50 mL of whole blood and 30 mL of EDTA blood was 121 
obtained from each subject. Blood was promptly centrifuged (3000 rpm at 4°C), and serum or 122 
plasma was aliquoted in polypropylene tubes that were immediately stored at -80°C. This 123 
study was funded by Programme Hospitalier de Recherche Clinique, French Ministry of 124 
Health, N° P081216 / IDRCB 2009-A00892-55, and was approved by the Paris-Sud Ethics 125 
Committee in November 2009. 126 
We also obtained serum samples from 81 consecutive patients with PHPT before parathyroid 127 
surgery. These patients were osteoporotic (low bone mineral density [BMD] and/or low-128 
trauma fracture) and were initially referred to our tertiary care centre for etiological diagnosis 129 
of abnormal calcium/phosphorus or related hormone levels detected during a screening 130 
biological evaluation aimed at ruling out secondary causes of osteoporosis. We requested that 131 
the physician who referred the patient prescribe vitamin D if the 25OHD concentration was 132 
low, before investigations in our unit. Based on the pharmaceutical forms available in France, 133 
the recommended supplementation scheme comprised four 100,000 IU vitamin D3 vials (one 134 
vial every other week) in case of serum 25OHD concentration <20 ng/mL, and two vials in 135 
case of 25OHD concentration between 20 and 29.9 ng/mL. According to the procedure in our 136 
unit, an oral calcium load test was performed in those with total calcium serum levels <3 137 
mmol/L at their initial work up (n=78). In those with normal serum calcium level, the oral test 138 
was followed by an IV calcium load test as described in 
13
. In all patients, an insufficient fall 139 
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in serum PTH when serum ionized calcium level rose well above the upper normal limit 140 
during the test was observed, confirming the diagnosis of PHPT. All had preoperative 141 
parathyroid imaging (echography and sestaMIBI scintigraphy) which was positive in 45 cases 142 
(44.4%) and negative or discrepant (negative at one of the test and positive at the other one) in 143 
36 Cases (55.6%). As they all had osteoporosis, these 81 consecutive patients were addressed 144 
to the surgeon and underwent successful parathyroidectomy, as confirmed by pathological 145 
examination of parathyroid tissue removed during surgery.  146 
Finally, we collected sera from 264 hemodialysis patients managed in the same dialysis 147 
department, just before a dialysis session. 148 
Laboratory methods 149 
The biological parameters of the healthy volunteer screening evaluation were determined 150 
locally by the laboratories attached to the clinical research units, using standard chemistry. 151 
The CKDepi formula was used to evaluate eGFR 
14
. PTH and 25OHD measurements were 152 
centralized and done in batches by means of immunochemiluminometric assays on the 153 
LIAISON XL (DiaSorin, Stillwater, Mn, USA), using serum samples that had never been 154 
thawed. According to data obtained by one of us (CM), intra-assay coefficient of variation 155 
(CV) were 3.2% at 25.7 ng/L and 3.2% at 284 ng/L for the 3
rd
-generation PTH assay, and 156 
2.2% at 17.9 ng/mL and 2.7% at 51.9 ng/mL for the 25OHD assay. Inter-assay CV were 157 
12.2% at 16.9 ng/L and 9.9% at 160 ng/L for the 3
rd
-generation PTH assay, and 9% at 17.9 158 
ng/mL and 7.9% at 34 ng/mL for the 25OHD assay. Limit of quantification was 4 ng/L and 4 159 
ng/mL for the 3
rd
-generation PTH assay, and for the 25OHD assay respectively. 160 
Statistical analysis 161 
Quantitative variables are reported as median, quartile (Q) 1 (25
th
 percentile), Q3 (75
th
 162 
percentile), and interquartile range (IQR). Associations between the serum PTH concentration 163 
and other quantitative variables were assessed by simple regression. The LOWESS 164 
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representation was used to smooth the relationship between PTH and 25OHD. Variables 165 
significantly associated with PTH were included in a model for multiple regression analysis. 166 
Variables significantly associated with PTH in multiple regression analysis were then 167 
stratified into arbitrarily defined subgroups, and the mean PTH values in these subgroups 168 
were compared by ANOVA. To determine the PTH reference range we first detected outliers, 169 
defined as PTH concentrations below Q1-1.5 IQR and above Q3+1.5 IQR after log 170 
transformation of the raw values 
15
. We then calculated the 95% confidence interval in the 171 
remaining subjects after eliminating the outliers. Percentages were compared by means of the 172 
chi² test. A p value <0.05 was considered significant. 173 
Results 174 
Healthy subjects  175 
Nine hundred seventy-two Caucasian subjects were initially recruited. Two were excluded 176 
because their informed consent was not available, and another 60 were excluded because of 177 
abnormal values in the screening evaluation. Among the remaining 910 subjects, no serum 178 
sample was available for PTH testing in 12 cases. The study population thus consisted of 898 179 
subjects, whose main characteristics are summarized in Table 1. The median PTH value in 180 
these 898 subjects was 18.8 ng/L (Q1: 15.2 ng/L; Q3: 24.0 ng/L; IQR: 8.8 ng/L). After 181 
excluding nine outliers (eight high values, one low value), the range of PTH values (2.5
th
-182 
97.5
th
 percentile) was 10.1-37.9 ng/L, with no significant difference between men and women 183 
(18.8 ng/L [15.2-24.0] and 19.1 ng/L [15.4-24.0] respectively; p=0.13). In simple regression 184 
analysis, serum PTH correlated negatively with serum 25OHD (r=-0.29; p<0.001), phosphate 185 
(r=-0.19; p<0.001), calcium (r=-0.16; p<0.001) and eGFR (r=-0.25; p<0.001), and positively 186 
with age (r=0.37; p<0.001), and BMI (r=0.20; p<0.001). In multiple regression analysis, only 187 
the 25OHD level and age remained significantly correlated with PTH. PTH concentrations in 188 
the 898 subjects are shown in Table 2 according to age and 25OHD concentrations. Figure 1 189 
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shows the relationship between 25OHD and PTH concentrations, represented by the 190 
LOWESS curve. No obvious inflection point (i.e. a 25OHD concentration above which PTH 191 
no longer decreases) is visible in this curve. It should be noted that few subjects had “high” 192 
25OHD levels as only 5 (0.5%) had a concentration above 50 ng/mL. 193 
As PTH concentrations were significantly lower in subjects with serum 25OHD ≥ 30 ng/mL 194 
(n=183) than in the other three 25OHD groups (Table 2), we used only these 183 subjects to 195 
establish our PTH reference range. The median PTH concentration in these 183 subjects was 196 
17.0 ng/L (Q1: 13.5 ng/L; Q3: 21.5 ng/L; IQR: 8.0 ng/L). After excluding six outliers with 197 
high values, the range (2.5
th
-97.5
th
 percentile) of PTH concentrations was 9.4-28.9 ng/L. In 198 
simple regression analysis, serum PTH levels in this group of 183 subjects correlated 199 
positively with age (r=0.30; p<0.001) and BMI (r=0.23; p=0.002), and negatively with eGFR 200 
(r=-0.22; p=0.002), but not with serum 25OHD (p=0.32). In multiple regression analysis, only 201 
age remained significantly associated with serum PTH. The median PTH concentration in 202 
subjects less than 60 years old (n=152) was 17.8 ng/L (2.5
th
-97.5
th
 percentile: 9.1-28.5 203 
pg/mL), a value significantly lower than in subjects aged 60 years or more (n=31) who had a 204 
median PTH concentration of  21.5 ng/L (p<0.001). No significant difference was found 205 
between subjects aged 18-29 years and those aged 30-59 years (p=0.09). In the 31 older 206 
subjects, the estimated range of PTH values was11-33 ng/mL. However, as this subgroup was 207 
small, we considered that it should not be used as reference values. Thus, for the following 208 
analyses in PHPT and dialysis patients, we used the range of PTH values obtained in the 209 
whole group of 183 subjects with serum 25OHD ≥ 30 ng/mL as our reference, that is 9.4-28.9 210 
ng/L. Interestingly, in the entire initial population of 898 apparently healthy subjects, 26 211 
(2.9%) had PTH concentrations >38.4 ng/L, corresponding to the ULN given by the kit 212 
manufacturer, while 114 (12.7%) had PTH concentrations >28.9 ng/L. Thus, 88 of our 898 213 
apparently healthy subjects (9.8%) would be considered as having elevated PTH 214 
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concentrations when using our upper normal limit of 28.9 ng/L, but normal PTH 215 
concentrations using the manufacturer’s ULN. 216 
PHPT patients  217 
The main characteristics of these 81 patients are presented in Table 3. All had a 25OHD 218 
serum concentration >20 ng/mL, and 52 had a 25OHD concentration >30 ng/mL. Using the 219 
manufacturer's ULN of 38.4 ng/L, 27 (33.3%) of our 81 PHPT patients had a “normal” PTH 220 
concentration. The percentage of “normal” PTH values (9.9%, 8/81) was significantly lower 221 
(chi²=13.1; p<0.001) when using our ULN of 28.9 ng/L. Figure 2 shows the relationship 222 
between serum total and ionized calcium levels in the 81 PHPT patients. Although well 223 
correlated (r=0.86; p<0.001), some discrepancies in the classification of the patients between 224 
both calcemia were noted. Twenty seven (33.3%) of our 81 PHPT patients had normal total 225 
calcemia (<2.60 mmol/L) and 12 (14.1%) had normal ionized calcemia (<1.30 mmol/L). One 226 
had normal ionized calcemia and high total calcemia. Thus, 11 (13.6%) of these 81 patients 227 
were considered as having true N-PHPT. None of these11 N-PHPT patients had a PTH 228 
concentration below 28.9 ng/L, while four (36.4%) had values below 38.4 ng/L. Among the 229 
27 patients with normal total calcemia, 12 had a PTH concentration below 38.4 ng/mL (5 of 230 
them with a ionized calcemia <1.30 mmol/L) and three had values below 28.9 ng/L.  231 
Dialysis patients 232 
The KDIGO guidelines recommend maintaining dialysis patients' serum PTH concentrations 233 
between two and nine times the ULN of the kit used in the laboratory. We thus determined the 234 
percentage of our 264 dialysis patients who had PTH levels below, within and above this 235 
target range, based on the manufacturer’s ULN of 38.4 ng/mL (76.8-345.6 ng/L) and on our 236 
ULN of 28.9 ng/L (57.8-251.1 ng/L). Their median PTH concentration was 179.5 ng/L [81.5-237 
272.0] (range 12.4-1750 ng/L). Forty-eight patients (18.2%) were classified differently with 238 
the two PTH ULN values used to calculate the KDIGO target range (Table 4). 239 
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 240 
Discussion 241 
We established PTH reference values for an automated 3
rd
-generation assay in a large group 242 
of French Caucasian healthy volunteers. When we included only subjects with 25OHD ≥ 30 243 
ng/mL and eGFR ≥ 60 mL/min/1.73 m², as recommended 
3
, the PTH ULN was 22.4% lower 244 
than the ULN usually applied by clinical laboratories using this kit (28.9 ng/mL instead of 245 
38.4 ng/L). 246 
One question addressed in recent guidelines for the diagnosis of asymptomatic PHPT is 247 
whether a 25OHD of 20 or 30 ng/mL should be considered as the concentration below which 248 
a subject should be excluded from a reference population for serum PTH values 
3
. Indeed, the 249 
higher the 25OHD cut-off defining low 25OHD levels, the lower the PTH ULN (as an 250 
example, the ULN that we calculated in our healthy subjects with a 25OHD concentration 251 
>20 ng/mL from the present study was 32.1 ng/L). It must be underlined that the 20 ng/mL 252 
cut-off, supported by the Institute of Medicine, is intended to establish optimal vitamin D 253 
intake in the general (healthy) population 
16
, while the 30 ng/mL cut-off is supported by the 254 
Endocrine Society and is intended for use in patient management 
17
. Since these 2011 255 
recommendations, the debate about the 25OHD threshold has continued 
18, 19
 with experts 256 
defending the 20 ng/mL value 
20
 and other the 30 ng/mL value 
21
. The choice is important, as 257 
it has a huge influence on the number of subjects that may be included in a “vitamin D-258 
replete” reference population for normal PTH values. Indeed, at least in France, 259 
approximately half the general healthy population and almost 80% have a 25OHD below 20 260 
ng/mL and 30 ng/mL, respectively 
6
. In our opinion, the 30 ng/mL cut-off should be used 261 
when recruiting “vitamin D-replete” subjects to establish PTH normal values, not because 262 
25OHD concentrations should always be above 30 ng/mL but rather because this cut-off 263 
would have more diagnostic value for detecting  HPT (either primary or secondary) when 264 
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interpreting a PTH concentration. Indeed, in the highly frequent case of a normocalcemic 265 
patient with an elevated PTH, the clinical question is whether the elevated PTH is due to 266 
vitamin D insufficiency or to N-PHPT (after all other causes of SHPT have been excluded). 267 
Many reports have concluded that PTH concentrations are sometimes elevated in subjects 268 
with 25OHD concentrations below 28-32 ng/mL 
22
. Having said that, we recognize that the 269 
debate on the optimal cut-off defining vitamin D sufficiency is “hot”, and that some scientists 270 
who do not accept the 30 ng/mL value will not accept our PTH ULN of 28.4 ng/L with this 3
rd
 271 
generation assay. For them, a PTH ULN of  32.1 ng/L (calculated in the population with 272 
25OHD>20 ng/mL) would be more appropriate.  273 
Another important question is whether the PTH reference values should be stratified for 274 
factors known to be associated with PTH levels, such as race, BMI and age. Indeed, serum 275 
PTH levels are higher in black than white people 
23
, in overweight individuals than lean 
24
, 276 
and in the elderly than the young 
25
. This may simply be due to differences in vitamin D 277 
status, as 25OHD levels are usually lower in blacks, in overweight persons, and in the elderly. 278 
The present study included only Caucasian subjects, and we were thus unable to determine 279 
whether race is independently associated with PTH levels. We found that BMI was not an 280 
independent determinant of PTH levels, in keeping with our findings in another cohort of 281 
healthy French subjects 
6
. Our results suggest that PTH reference values should be stratified 282 
for age, as subjects older than 60 years had higher PTH concentrations than younger subjects, 283 
independently of vitamin D status and renal function. However, given the small number of 284 
“vitamin D-replete” subjects over 60 years old, we were unable to provide separate reference 285 
values for younger and older subjects. 286 
As stressed above, taking vitamin D status into account when establishing PTH reference 287 
values leads to a lower ULN than generally obtained in apparently healthy general 288 
populations. The obvious consequence is that above-normal concentrations will be found 289 
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more often in clinical practice. On the one hand, this will improve the diagnostic sensitivity of 290 
PTH assay, as witnessed by the higher frequency of elevated PTH concentrations among our 291 
patients with surgically proven PHPT. Even if high calcium and PTH in the upper normal 292 
range is usually accepted as a diagnostic criterion of PHPT (the PTH is abnormally high-293 
normal in face of hypercalcemia), many doctors feel more “comfortable” with the diagnosis 294 
of PHPT when both parameters are elevated. However, even with our lower ULN, almost 295 
10% of our PHPT patients still had “normal” PTH values, emphasizing the need to interpret 296 
serum PTH concentrations with respect to calcemia. Importantly, our PHPT diagnoses were 297 
based on total and ionized calcemia, a calcium load test, and a lower PTH ULN. It may be 298 
noted that the calcium load test is not a standard diagnostic procedure for PHPT in most units. 299 
Indeed, high PTH and (even moderately) high total or ionized calcemia is usually considered 300 
sufficient. It is however systematic in our unit and has proved to be extremely helpful in 301 
normocalcemic patients.  The superiority of ionized calcium over total calcium for the 302 
diagnosis of PHPT has been reported by others 
26
 and is confirmed by our data showing that a 303 
proportion of our surgically-proven PHPT patients had an elevated pre-surgery ionized serum 304 
calcium and a normal serum total serum calcium level (see Figure 2). Assuming that ionized 305 
calcium is seldom measured routinely in clinical practice, and that most laboratories use a 306 
higher PTH ULN than ours, the diagnosis of PHPT would probably have been missed in 12 307 
(12.8%) of our 81 patients, as they had both normal total calcemia and PTH <38.4 ng/L. On 308 
the other hand, use of our PTH reference values might lead to lower specificity. In a previous 309 
study, we verified that PTH reference values for the Nichols Allegro PTH assay established in 310 
vitamin D-replete subjects did not affect diagnostic specificity: as expected, PTH 311 
concentrations were "above-normal" in only 3% of 360 consecutive osteoporotic patients with 312 
no reason for having high PTH levels, based on their medical charts and extensive biological 313 
investigation 
27
. We must underline that our PHPT population does not reflect PHPT patients 314 
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in general. First, all had osteoporosis, and, second, the proportion of normocalcemic patients 315 
may seem very high. This is probably due to a selection bias related to the fact that our unit is 316 
specialized in the exploration of calcium/phosphorus metabolism in patients with bone 317 
diseases, and that many of these patients were referred because of very mild 318 
calcium/phosphorus and/or PTH abnormalities detected during the work-up of osteoporosis 319 
(to exclude a secondary cause of bone fragility). Furthermore, although it is clearly stated in 320 
the recent guidelines for the management of asymptomatic PHPT that “N-PHPT is now a 321 
well-recognized variant of PHPT” 
7
, and that “N-PHPT is part of the diagnostic spectrum of 322 
PHPT, and we need to ensure a correct diagnosis…” 
3
, there is a lack of recommendations 323 
concerning the treatment of this entity (Surgery or not ?). In these patients, our practice is to 324 
propose parathyroidectomy if they meet one or several of the indications for parathyroid 325 
surgery that are proposed in the guidelines
7
. As all our PHPT patients had osteoporosis, they 326 
were all addressed for parathyroid surgery to the same experienced surgeon, even in case of 327 
negative preoperative imaging. We have previously shown that hypercalcemic PHPT and N-328 
PHPT patients had a similar BMD gain at the spine and at the hip one year after 329 
parathyroidectomy
13
. 330 
The KDIGO recommendation to maintain PTH levels between two and nine times the ULN in 331 
dialysis patients deserves some discussion. SHPT is frequently associated with CKD and may 332 
be considered an appropriate adaptive response to decreasing GFR aimed at maintaining 333 
calcium/phosphorus homeostasis. However, SHPT may have deleterious consequences for 334 
bone turnover and mineralization and, in its severe forms, may lead to osteitis fibrosa cystica. 335 
SHPT may also become autonomous, leading to tertiary (hypercalcemic) 336 
hyperparathyroidism. However, many patients with CKD do not exhibit a sufficient increase 337 
in PTH levels with often a low bone turnover. This so-called adynamic bone disease is 338 
associated with a tendency to hypercalcemia and an increased risk of vascular calcification. 339 
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Thus, PTH levels should be neither too high nor too low in CKD patients, especially in case 340 
of dialysis, leading experts to propose an optimal range for PTH serum levels. However, 341 
marked inter-method variability in serum PTH values precludes the use of a PTH target range 342 
(expressed in ng/L) applicable to all PTH assay methods 
28-30
. This is why KDIGO proposes a 343 
PTH target range based on multiples of the ULN rather than on absolute concentrations. The 344 
range of 2 to 9 times the ULN was chosen because several studies showed that values below 345 
and above these limits were frequently associated with severely impaired bone turnover on 346 
biopsy 
31
, and with increased cardiovascular morbidity and mortality 
32, 33
. Although a PTH 347 
target range based on ULN multiples is a pragmatic way of overcoming the inter-method 348 
variability of PTH measurement, the way in which normal PTH values are established is of 349 
paramount importance. Indeed, with a given PTH assay the ULN may vary significantly 350 
depending on the reference population. Here, 18.6% of our dialysis patients were classified 351 
differently with our ULN of 28.9 ng/L compared to the manufacturer's ULN of 38.4 ng/L. 352 
This is consistent with what we have previously found on comparing the manufacturers' 353 
reference ranges for 10 different PTH kits with the reference ranges that we established in the 354 
same population of vitamin D-replete Belgian healthy subjects for the 10 kits 
9
. This 355 
variability may influence the therapeutic choices of nephrologists, who are used to adapting 356 
the dosages of PTH treatments, such as active vitamin D and calcimimetics, according to 357 
KDIGO recommendations for PTH values. 358 
It must be underlined that, as in our previous studies on the same topic 
6, 9-12
, the blood 359 
samples used here were obtained in the morning (7:30-9:30 AM) after an overnight fast. 360 
Indeed, the ULN for a 2
nd
-generation PTH assay obtained in healthy persons sampled in a non 361 
fasting state over a larger time span was higher than in our studies 
34
 (see discussion in 
6
).  362 
The main strengths of our study pertain to the large number of healthy subjects; the 363 
population-based recruitment with strict inclusion criteria; the ability to stratify PTH 364 
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concentrations by 25OHD status, gender, renal function, and BMI; centralization of PTH 365 
assay in a single laboratory; and the use of a 3
rd
-generation assay, which is increasingly 366 
employed worldwide. Its limitations must also be acknowledged. First, although large, our 367 
population of healthy subjects was insufficient to propose separate reference values for 368 
younger and older adults. Second, we restricted the study to Caucasian adults and were 369 
therefore unable to determine whether PTH reference values should be stratified according to 370 
ethnicity. Third, we did not rule out certain causes of PTH elevation in apparently healthy 371 
adults that might influence PTH ULN, such as very low calcium intake or renal calcium 372 
leakage. However, we believe that the use of the Horn algorithm, which allowed us to identify 373 
and eliminate outliers, minimized this problem. Fourth, as the control of PTH secretion is 374 
very complex, other variables not considered in the present study such as daily calcium intake 375 
or plasma FGF23 may influence PTH normative data. Fifth, as indicated above, our PTH 376 
ULN only applies for this 3
rd
-generation PTH assay, and if the target 25OHD serum level of 377 
30 ng/mL is accepted. 378 
In conclusion, we confirm that serum PTH reference values are highly dependent on the 379 
characteristics of the reference population, especially vitamin D status, renal function, and 380 
age. Inclusion of only vitamin D-replete subjects with an eGFR ≥ 60 mL/min/1.73 m² reduced 381 
the upper normal limit of the reference range by 22.4% compared to the usual reference 382 
values of the LIAISON 3
rd
-generation PTH assay. This had two consequences: 1) it 383 
significantly increased the prevalence of elevated PTH values in patients with surgically 384 
proven PHPT and, thus, the diagnostic sensitivity of PTH assay for PHPT, and 2) it modified 385 
the classification of dialysis patients based on the PTH target range recommended by KDIGO 386 
guidelines. As massive inter-method variability in PTH assay results has been demonstrated, 387 
more studies are needed to establish PTH reference values for all available assays, using the 388 
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same large population of vitamin D-replete healthy subjects with normal eGFR and stratifying 389 
the data according to age and, possibly, ethnicity.  390 
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Legends  535 
Figure 1: Relationship between serum PTH and 25OHD concentrations in 898 healthy French 536 
subjects. The solid curve is the Lowess representation of the relationship. 537 
Figure 2 : Pre-surgery serum total calcium levels of the 81 surgically-proven PHPT patients 538 
plotted against their pre-surgery ionized serum calcium level. The vertical line marks the 539 
ULN of total serum calcium level in our laboratory (2.60 mmol/L). The horizontal line marks 540 
ULN of ionized serum calcium level in our laboratory (1.30 mmol/L). Dots in the upper left 541 
quadrant correspond to patients with an elevated ionized calcemia and a normal total 542 
calcemia. One patient had a slightly elevated total calcemia (2.62 mmol/L) and a high normal 543 
ionized calcemia (1.30 mmol/L). 544 
 545 
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 Table 1. Characteristics of the healthy subjects participating in the VARIETE study. 
 Median [Q1-Q3] (min-max) 
Gender:  men/women 466/432 
Age (years) 32 [24-54] (18- 89) 
BMI (kg/m²) 22.9 [21.1-24.8] (18.5-28) 
Serum 25OHD (ng/mL) 18.8 [15.2-24.0] (7.4-79.0) 
Serum PTH (ng/L) 23.6 [18.8-28.3] (5.2-59.4) 
Serum calcium (mmol/L) 2.30 [2.21-2.39] (2.10-2.60) 
Serum phosphate (mmol/L) 1.10 [0.97-1.22] (0.75-1.51) 
Serum albumin (g/L) 43.0 [40.0-46.0] (32.6-50) 
eGFR (CKDepi) (mL/min/1.73 m²) 101 [88-114] (60-144) 
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 Table 2: PTH concentrations in the normal subjects of the VARIETE study, according to age 
and serum 25OHD levels. 
 n PTH (ng/L): 
median [Q1-Q3] 
P value 
Age:        a) 18-29 years 
                 b) 30-59 years 
                 c) > 60 years  
411 
307 
180 
16.9 [14.1-21.2] 
18.9 [15.3-24.4] 
23.5 [18.9-31.7] 
versus b) and c): p<0.001 
versus a) and c): p<0.001 
versus a) and b): p<0.001 
25OHD  a) <12 ng/mL 
               b) 12-19.9 ng/mL 
               c) 20-29.9 ng/mL 
               d) >30 ng/mL  
66 
208 
441 
183 
26.5 [18.6-33.7] 
20.5 [16.4-26.5] 
18.0 [15.1-22.7] 
17.0 [13.5-21.5] 
versus b), c), and d): p<0.001 
versus a), c), and d): p<0.001 
versus a) and b): p<0.001; versus d): p=0.04 
versus a) and b): p<0.001; versus c): p=0.04 
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 Table 3 : Main characteristics of the 81 patients with PHPT 
Gender : men/women 4/77 
Age (years) 67 [57-76]  
(min : 28-max: 91) 
Serum total calcium (mmol/L) 2.64 [2.55-2.75] 
Serum ionized calcium (mmol/L) 1.38 [1.32-1.44] 
Serum 25OHD (ng/mL) 32 [26-39] 
Serum 3rd-generation PTH (ng/L) 46.0 [36.6-65.5] 
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 Table 4: Classification of dialysis patients (n=264) according to the KDIGO target range (two 
to 9 times the PTH ULN) based on our ULN of 28.9 ng/L and on the manufacturer’s ULN of 
38.4 ng/L 
 Patients (n [%]) with a PTH 
concentration below, within or 
above the KDIGO target range 
based on the manufacturer’s 
ULN  
(76.8-345.6 ng/L) 
Patients (n [%]) having a 
PTH concentration below, 
within or above the KDIGO 
target range based on our 
ULN  
(57.8-251.1 ng/L) 
Below the target range 64 (24.2%) 50 (18.9%) 
Within the target range 154 (58.3%) 134 (50.8%) 
Above the target range 46 (21.6%) 80 (30.3%) 
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Figure 1: Relationship between serum PTH and 25OHD concentrations in 898 healthy French subjects. The 
solid curve is the Lowess representation of the relationship.  
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Figure 2 : Pre-surgery serum total calcium levels of the 81 surgically-proven PHPT patients plotted against 
their pre-surgery ionized serum calcium level. The vertical line marks the ULN of total serum calcium level in 
our laboratory (2.60 mmol/L). The horizontal line marks ULN of ionized serum calcium level in our 
laboratory (1.30 mmol/L). Dots in the upper left quadrant correspond to patients with an elevated ionized 
calcemia and a normal total calcemia. One patient had a slightly elevated total calcemia (2.62 mmol/L) and 
a high normal ionized calcemia (1.30 mmol/L).  
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